Diagnostic means and methods using troponin t and nt-probnp

A method of determining whether a human subject suffering from cardiac necrosis is susceptible for a therapy against initial heart failure, the method comprising the steps of

• determining an amount of troponin T and an amount of NT-pro BNP in a sample from the subject and
• comparing the amount of the troponin T determined with a reference amount of troponin T and comparing the amount of NT proBNP determined with a reference amount of NT-proBNP,
• whereby it is further determined whether the subject is susceptible to a therapy against initial heart failure.

A method for determining whether a human subject suffering from cardiac necrosis is susceptible for a therapy against coronary heart disease, the method comprising the steps of determining an amount of troponin T and an amount of NT-proBNP in a sample from the subject and

• comparing the amount of the troponin T determined with a reference amount of troponin T and comparing the amount of NT proBNP determined with a reference amount of NT-proBNP, whereby it is further determined whether the subject is susceptible to a therapy against coronary heart disease.

A method of monitoring success of a therapy against coronary heart disease in a human subject, the method comprising the steps of

• determining an amount of troponin T in a first sample from the subject wherein the first sample has been obtained prior to the therapy,
• determining an amount of troponin T in a second sample from the subject wherein the second sample has been obtained following the therapy, and
• comparing the amounts determined from the first and the second samples, whereby a decrease in the amount of troponin T in the second sample versus the first sample is indicative of success of the therapy.

A method of monitoring success of a therapy against initial heart failure in a human subject, the method comprising the steps of

• determining an amount of troponin T and an amount of NT-proBNP in a first sample from the subject wherein the first sample has been obtained prior to the therapy,
• determining an amount of troponin T and an amount of NT-proBNP in a second sample from the subject wherein the second sample has been obtained following the therapy, and
• comparing the amounts of troponin T determined from the first and the second samples and comparing the amounts of NT-proBNP determined from the first and second samples, whereby a decrease in the amount of troponin T and a decrease in the amount of NT-proBNP is indicative for success of the therapy.